10x Genomics Zukünftiges Wachstum
Future Kriterienprüfungen 1/6
10x Genomics is forecast to grow earnings and revenue by 13.3% and 5.8% per annum respectively. EPS is expected to grow by 14.3% per annum. Return on equity is forecast to be -13.9% in 3 years.
Wichtige Informationen
13.3%
Wachstumsrate der Gewinne
14.3%
EPS-Wachstumsrate
| Life Sciences Gewinnwachstum | 19.8% |
| Wachstumsrate der Einnahmen | 5.8% |
| Zukünftige Eigenkapitalrendite | -13.9% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 30 Oct 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 694 | -99 | -24 | 70 | 12 |
| 12/31/2025 | 635 | -149 | -94 | 58 | 16 |
| 12/31/2024 | 599 | -171 | -163 | 19 | 16 |
| 9/30/2024 | 630 | -183 | 25 | 39 | N/A |
| 6/30/2024 | 632 | -240 | -33 | -8 | N/A |
| 3/31/2024 | 625 | -264 | -74 | -27 | N/A |
| 12/31/2023 | 619 | -255 | -65 | -15 | N/A |
| 9/30/2023 | 591 | -223 | -113 | -27 | N/A |
| 6/30/2023 | 568 | -172 | -118 | -11 | N/A |
| 3/31/2023 | 536 | -174 | -126 | -17 | N/A |
| 12/31/2022 | 516 | -166 | -165 | -34 | N/A |
| 9/30/2022 | 504 | -167 | -161 | -42 | N/A |
| 6/30/2022 | 498 | -142 | -161 | -58 | N/A |
| 3/31/2022 | 499 | -89 | -129 | -38 | N/A |
| 12/31/2021 | 490 | -58 | -123 | -21 | N/A |
| 9/30/2021 | 459 | -455 | -253 | -157 | N/A |
| 6/30/2021 | 406 | -504 | -264 | -187 | N/A |
| 3/31/2021 | 333 | -533 | -289 | -219 | N/A |
| 12/31/2020 | 299 | -543 | -256 | -218 | N/A |
| 9/30/2020 | 262 | -134 | -104 | -81 | N/A |
| 6/30/2020 | 251 | -78 | -46 | -11 | N/A |
| 3/31/2020 | 264 | -49 | -19 | 23 | N/A |
| 12/31/2019 | 246 | -31 | -8 | 35 | N/A |
| 9/30/2019 | 221 | -100 | -62 | -23 | N/A |
| 6/30/2019 | 197 | -105 | -69 | -43 | N/A |
| 3/31/2019 | 170 | -105 | -71 | -57 | N/A |
| 12/31/2018 | 146 | -112 | -83 | -76 | N/A |
| 12/31/2017 | 71 | -19 | N/A | -11 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: 0A88 is forecast to remain unprofitable over the next 3 years.
Ertrag vs. Markt: 0A88 is forecast to remain unprofitable over the next 3 years.
Hohe Wachstumserträge: 0A88 is forecast to remain unprofitable over the next 3 years.
Einnahmen vs. Markt: 0A88's revenue (5.8% per year) is forecast to grow faster than the UK market (3.6% per year).
Hohe Wachstumseinnahmen: 0A88's revenue (5.8% per year) is forecast to grow slower than 20% per year.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: 0A88 is forecast to be unprofitable in 3 years.